Dual-listed AFT Pharmaceuticals has reported strong earnings across its markets, with strong sales growth in its Australasian medicines business and growing sales of its Maxigesic brand of pain treatment as well as increased hospital antibiotics and vitamin C sachet sales attributed to Covid-19
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
